Sipuleucel-T is cellular immunotherapy that contains re-engineered immune cells originally derived from the patient. The dose administered contains at least 50 million patient CD54+ cells that are activated with PAP-GM-CSF.
The therapy is indicated for the treatment of asymptomoatic or minimally symptomatic metastatic castrate-resistant prostate cancer.